The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B (PARTNERII B)
The PARTNER II Trial "Placement of AoRTic TraNscathetER" Valves Trial" (US) [PII B] for Inoperable Patients
調査の概要
状態
詳細な説明
Cohort B was a 1:1 randomized, controlled study independently powered to compare transcatheter heart valve therapy with the first generation (SAPIEN™ THV) system to transcatheter heart valve therapy with the second generation (SAPIEN XT THV) system in patients who could not undergo surgery (inoperable).
Patients in the control arm of Cohort B received an Edwards SAPIEN THV with the associated delivery system while patients in the treatment arm of Cohort B received an Edwards SAPIEN XT THV with the associated delivery system.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72211
- Arkansas Heart Hospital/Clinic
-
-
California
-
La Jolla、California、アメリカ、92037
- Scripps Green Hospital
-
La Jolla、California、アメリカ、92037
- Scripps Memorial Hospital
-
Los Angeles、California、アメリカ、90048
- Cedars-Sinai Medical Center
-
Sacramento、California、アメリカ、95816
- Mercy General Hospital
-
Stanford、California、アメリカ、94305
- Stanford University Medical Center
-
-
Colorado
-
Denver、Colorado、アメリカ、80045
- University of Colorado Hospital
-
-
District of Columbia
-
Washington、District of Columbia、アメリカ、20010
- Washington Hospital Center (WHC)
-
-
Florida
-
Clearwater、Florida、アメリカ、33756
- Morton Plant Hospital
-
Gainesville、Florida、アメリカ、32610
- University of Florida, Gainesville
-
Miami、Florida、アメリカ、33136
- University of Miami
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- Emory University Hospital
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush University Medical Center
-
Chicago、Illinois、アメリカ、60611
- Northwestern Hospital
-
Springfield、Illinois、アメリカ、62701
- Prairie Education And Research Cooperative
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University Health-Methodist Hospital
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- The University of Iowa
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- University of Louisville - Jewish Hospital
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Brigham and Women's Hospital
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
Royal Oak、Michigan、アメリカ、48073
- William Beaumont Hospital
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55407
- Minneapolis Heart Institute Foundation
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Hospital of Kansas City Mid America
-
Saint Louis、Missouri、アメリカ、63110
- Washington University - Barnes Jewish Hospital
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68526
- Nebraska Heart Institute
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Newark、New Jersey、アメリカ、07112
- Newark Beth Israel
-
-
New York
-
Manhasset、New York、アメリカ、11030
- North Shore University Hospital, NY
-
Mineola、New York、アメリカ、11501
- Winthrop University Hospital
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
New York、New York、アメリカ、10021
- Cornell University
-
-
North Carolina
-
Charleston、North Carolina、アメリカ、29425
- Medical University of South Carolina Charleston
-
Greenville、North Carolina、アメリカ、27834
- East Carolina Heart Institute at East Carolina University
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- The Christ Hospital, Cincinnati
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73135
- Oklahoma Heart Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania Hospital
-
York、Pennsylvania、アメリカ、17403
- York Hospital
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38120
- Baptist Memorial Hospital
-
-
Texas
-
Austin、Texas、アメリカ、78756
- Austin Heart, PLLC
-
Dallas、Texas、アメリカ、75230
- Medical City Dallas Hospital
-
Dallas、Texas、アメリカ、75093
- The Heart Hospital Baylor Plano
-
Houston、Texas、アメリカ、77030
- The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center
-
San Antonio、Texas、アメリカ、78229-3900
- University of Texas Health Science Center at San Antonio (UTHSCSA)
-
-
Utah
-
Murray、Utah、アメリカ、84157
- Intermountain Medical Center
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22904
- University of Virginia
-
Norfolk、Virginia、アメリカ、23507
- Sentara Norfolk General Hospital
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- University of Washington
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin - Madison
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- Patient was symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
- The probability of death or serious, irreversible morbidity is greater than or equal to 50%.
- The heart team agreed (and verified in the case review process) that valve implantation would likely benefit the patient.
- The study patient or the study patient's legal representative was informed of the nature of the study, agreed to its provisions and had provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
- The study patient agreed to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which was conducted as a phone follow-up.
Exclusion Criteria
- Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.
- Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta. (Transfemoral)
- Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- It is known that the patient is currently enrolled in the PARTNER I Trial or was withdrawn from the PARTNER I Trial prior to endpoint analysis.
- Active bacterial endocarditis within 6 months (180 days) of procedure.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:TAVR - SAPIEN XT
TAVR (transaortic valve replacement) with SAPIEN XT
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
アクティブコンパレータ:TAVR - SAPIEN
TAVR (transaortic valve replacement) with SAPIEN is the control arm
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of Participants With All-Cause Mortality and/or Major Stroke and/or Rehospitalization
時間枠:1 Year
|
All-Cause Mortality and/or Major Stroke and/or Rehospitalization at 1 Year
|
1 Year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
NYHA Classification - Change From Baseline
時間枠:Baseline and 1 Year
|
New York Heart Association (NYHA), functional classification of heart failure based on how much a patient is limited during physical activity.
The rating ranges from I - IV, with the lowest as no limitations and the highest unable to carry on any physical activity without discomfort.
|
Baseline and 1 Year
|
Total Aortic Regurgitation - Change From Baseline
時間枠:1 Year
|
Total aortic regurgitation was assessed by the core lab as 'Grade 0' = None, 'Grade 1+' = Trace, 'Grade 2+' = Mild, 'Grade 3+' = Moderate, and 'Grade 4+' = Severe. Total regurgitation at one year was analyzed in the valve implant population. |
1 Year
|
Effective Orifice Area - Change From Baseline
時間枠:1 Year
|
1 Year
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Martin B Leon, MD、Columbia University
出版物と役立つリンク
一般刊行物
- Chen S, Redfors B, O'Neill BP, Clavel MA, Pibarot P, Elmariah S, Nazif T, Crowley A, Ben-Yehuda O, Finn MT, Alu MC, Vahl TP, Kodali S, Leon MB, Lindman BR. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry. Eur Heart J. 2020 Feb 21;41(8):958-969. doi: 10.1093/eurheartj/ehz892.
- Summers MR, Leon MB, Smith CR, Kodali SK, Thourani VH, Herrmann HC, Makkar RR, Pibarot P, Webb JG, Leipsic J, Alu MC, Crowley A, Hahn RT, Kapadia SR, Tuzcu EM, Svensson L, Cremer PC, Jaber WA. Prosthetic Valve Endocarditis After TAVR and SAVR: Insights From the PARTNER Trials. Circulation. 2019 Dec 10;140(24):1984-1994. doi: 10.1161/CIRCULATIONAHA.119.041399. Epub 2019 Nov 6.
- Furer A, Chen S, Redfors B, Elmariah S, Pibarot P, Herrmann HC, Hahn RT, Kodali S, Thourani VH, Douglas PS, Alu MC, Fearon WF, Passeri J, Malaisrie SC, Crowley A, McAndrew T, Genereux P, Ben-Yehuda O, Leon MB, Burkhoff D. Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement: Analysis of the PARTNER 2 Trials. Circ Heart Fail. 2019 Aug;12(8):e005809. doi: 10.1161/CIRCHEARTFAILURE.118.005809. Epub 2019 Aug 1.
- Genereux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, Kapadia S, Thourani VH, Mack MJ, Nazif TM, Lindman BR, Babaliaros V, Vincent F, Russo M, McCabe JM, Gillam LD, Alu MC, Hahn RT, Webb JG, Leon MB, Cohen DJ. Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement. J Am Coll Cardiol. 2022 Aug 23;80(8):783-800. doi: 10.1016/j.jacc.2022.05.006. Epub 2022 May 17.
- Shahim B, Redfors B, Lindman BR, Chen S, Dahlen T, Nazif T, Kapadia S, Gertz ZM, Crowley AC, Li D, Thourani VH, Kodali SK, Zajarias A, Babaliaros VC, Guyton RA, Elmariah S, Herrmann HC, Cohen DJ, Mack MJ, Smith CR, Leon MB, George I. Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Heart Assoc. 2022 Jun 7;11(11):e024091. doi: 10.1161/JAHA.121.024091. Epub 2022 Jun 3.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
TAVR Implantation with SAPIEN XTの臨床試験
-
Edwards Lifesciences完了
-
Edwards Lifesciences完了症候性の重度の大動脈弁狭窄症アメリカ, カナダ
-
Edwards Lifesciences積極的、募集していないファロー四徴症 | 肺疾患 | 先天性心疾患 | 肺逆流 | 経カテーテル肺動脈弁置換術 (TPVR)アメリカ
-
Edwards Lifesciences完了大動脈弁狭窄症 | 心筋症、肥大型アメリカ, カナダ
-
Edwards Lifesciences完了
-
Boston Scientific Corporation募集